Fund shareholders of Corcept Therapeutics Inc
ISIN US2183521028 · United States · LEI 529900EO9LUTFMZ7FF90
- Fund shareholders
- 303
- Of which ETFs
- 87 216 other funds
- Value held
- ≈ 2.9B $ 2.9B $ · 87.3K € · 11.1M SEK
- Share of capital
- 30.5 % of 108.1M shares on Jul 22, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) 1500 Momentum Tilt ETF SPDR SERIES TRUST | 11 | 956.5 $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| GVC GAESCO ZEBRA US SMALL CAPS LOW POPULARITY, FI GVC GAESCO GESTIÓN, SGIIC, S.A. | 51.7K € | 0.40 % | as of Dec 31, 2025 ↗ | ||
| NORTH CAPE INVERSIONES, S.A., SICAV ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 35.6K € | 0.28 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Tanaka Growth Fund TANAKA FUNDS INC | 9.14 % | as of May 31, 2026 ↗ |
| Pacer S&P SmallCap 600 Quality FCF Aristocrats ETF Pacer Funds Trust | 6.12 % | as of Jul 31, 2026 ↗ |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 5.60 % | as of Jun 30, 2026 ↗ |
| F/m Emerald Special Situations ETF RBB Fund, Inc. | 5.38 % | as of Jul 31, 2026 ↗ |
| Invesco Pharmaceuticals ETF Invesco Exchange-Traded Fund Trust | 4.96 % | as of Jul 31, 2026 ↗ |
| F/m Emerald Life Sciences Innovation ETF RBB Fund, Inc. | 4.79 % | as of May 31, 2026 ↗ |
| Invesco S&P SmallCap Health Care ETF Invesco Exchange-Traded Fund Trust II | 3.47 % | as of May 31, 2026 ↗ |
| Formidable ETF ETF Opportunities Trust | 3.45 % | as of Jun 30, 2026 ↗ |
| Simplify Propel Opportunities ETF Simplify Exchange Traded Funds | 2.98 % | as of Jun 30, 2026 ↗ |
| Allspring SMID Core ETF ALLSPRING EXCHANGE-TRADED FUNDS TRUST | 2.51 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 300 | +16 | 32,917,493 | +2.4 % |
| 2026Q2 | 284 | -90 | 32,151,667 | -3.7 % |
| 2026Q1 | 374 | -7 | 33,372,749 | +3.9 % |
| 2025Q4 | 381 | +5 | 32,120,398 | -2.4 % |
| 2025Q3 | 376 | +28 | 32,915,466 | -7.4 % |
| 2025Q2 | 348 | +39 | 35,553,672 | -0.0 % |
| 2025Q1 | 309 | +9 | 35,558,091 | -4.3 % |
| 2024Q4 | 300 | +22 | 37,163,380 | +1.6 % |
| 2024Q3 | 278 | +3 | 36,586,469 | +1.2 % |
| 2024Q2 | 275 | +1 | 36,163,901 | +7.4 % |
| 2024Q1 | 274 | +3 | 33,684,755 | +1.2 % |
| 2023Q4 | 271 | 33,273,095 |
Institutional managers
340 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 12,151,276 | 489.8M $ | as of Mar 31, 2026 |
| INGALLS & SNYDER LLC | 7,608,716 | 306.7K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 5,682,783 | 229.1M $ | as of Mar 31, 2026 |
| Parallel Advisors, LLC | 3,977,404 | 160.3M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 3,200,946 | 129M $ | as of Mar 31, 2026 |
| FMR LLC | 3,190,192 | 128.6M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,713,519 | 109.4M $ | as of Mar 31, 2026 |
| FIRST TRUST ADVISORS LP | 2,173,376 | 87.6M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,553,135 | 62.6M $ | as of Mar 31, 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1,500,000 | 60.5M $ | as of Mar 31, 2026 |
| UBS Group AG | 1,363,668 | 55M $ | as of Mar 31, 2026 |
| D. E. Shaw & Co., Inc. | 1,181,348 | 47.6M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,119,959 | 45.1M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 1,018,845 | 41.1M $ | as of Mar 31, 2026 |
| MPM BIOIMPACT LLC | 985,700 | 39.7M $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 945,884 | 38.1M $ | as of Mar 31, 2026 |
| Cerity Partners LLC | 731,689 | 29.5M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 725,822 | 29.3M $ | as of Mar 31, 2026 |
| Sio Capital Management, LLC | 674,759 | 27.2M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 643,158 | 25.9M $ | as of Mar 31, 2026 |
| Invesco Ltd. | 628,384 | 25.3M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 558,747 | 22.5M $ | as of Mar 31, 2026 |
| Bank of New York Mellon Corp | 543,757 | 21.9M $ | as of Mar 31, 2026 |
| Boston Trust Walden Corp | 462,606 | 18.6M $ | as of Mar 31, 2026 |
| PRINCIPAL FINANCIAL GROUP INC | 455,248 | 18.4M $ | as of Mar 31, 2026 |
Declared shareholders of Corcept Therapeutics Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Renaissance Technologies LLC and 1 other | 4.90 % | 5,261,628 | as of Apr 1, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Corcept Therapeutics Inc". https://titelia.com/en/stocks/corcept-therapeutics-inc-US2183521028